Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Pershing Square offers slate for Allergan board

Published 07/07/2014, 21:01
Pershing Square offers slate for Allergan board
AGN_pa
-
BHC
-

(Reuters) - William Ackman's Pershing Square Capital Management proposed on Monday a slate of six directors for the board of Allergan Inc as the hedge fund presses forward with its $53 billion (30.94 billion pounds) takeover bid with Valeant Pharmaceuticals International Inc for the Botox maker.

Pershing Square nominated Betsy Atkins, chief executive officer of venture capital firm Baja; Cathleen Black, senior adviser at RRE Ventures who was also a former chancellor of New York City's public schools and a former president of Hearst Magazines; Fredric Eshelman of investment firm Eshelman Ventures; Steven Shulman, managing director of Shulman Ventures, a private equity firm; David Wilson, former CEO of the Graduate Management Admission Council, and John Zillmer, former executive chairman of chemicals distributor Univar Inc.

Allergan is best known for Botox, an anti-wrinkle injection. Botox is also used to treat other medical conditions, including chronic migraine headaches.

Pershing Square is pushing for a special meeting of Allergan shareholders to consider the removal of six incumbent directors and the appointment of its slate of nominees.

Canada's Valeant has said it already has enough shareholders on its side to call the meeting. It would need the support of holders of at least 25 percent of the shares.

Allergan, based in Irvine, California, said its current board includes people with significantly more industry experience than Pershing Square's nominees.

© Reuters. Ackman, founder and CEO of hedge fund Pershing Square Capital Management, speaks at the Sohn Investment Conference in New York

"We believe today's announcement is a further attempt by co-bidders Pershing Square and Valeant to acquire Allergan at a grossly inadequate price that substantially undervalues the Company and creates significant risks and uncertainties for Allergan stockholders," an Allergan spokesperson said.

Allergan is expected to unveil details of its plan to remain a stand-alone company when it releases second-quarter results sometime in July. The company has said it is considering acquisitions of its own, additional spending cuts or taking on debt to buy back shares.

(Reporting by Susan Kelly in Chicago; Editing by Jan Paschal)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.